1. Insulin, Glucagon & Diabetes mellitus ENDOCRINE HORMONE

8. Islet

11. Pancreas Insulin secretagogue Sulphonylureas Meglitinides, GLP-1 Pancreas – 3 types of cells 1.a cell (5-10%) – secrete glucagon 2.b cells (70-80%) – secrete insulin 3.d cells (5%) – secrete somatostatin  cells  cell

12. Diabetes Diabetes mellitus is a heterogeneous group of metabolic disorders characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. (American Diabetes Association 2001) Defective Insulin secretion Defective Insulin action  Absolute insulin Diabetes

13. Symptoms of Diabetes 1.Polydipsia (Excessive thirst, dry mouth) 2.Polyuria (excessive urination) 3.Tiredness, fatigue, irritability 4.Recent change in weight. 5.Polyphagia (increased food consumption) 6.Blurring of vision 7.Nausea, headache

14. Complication of Diabetes 1.Macrovascular complication - Coronary and peripheral vascular disease - hypertension 2. Microvascular complication - Retinopathy with potential blindness - Neuropathies with risk of foot ulcer, amputation. - Nephropathy that may lead to renal failure. - Reduce resistance to infection Diabetes is a complex heterogeneous disease where multiple levels of abnormalities are present in various tissues. Defects of diabetes mellitus include long-term damage, dysfunction and failure of various organs. The major long-term complications of diabetes mellitus are macrovascular and microvascular diseases such as nephropathy, retinopathy and neuropathy

15. Diabetes - classification 1.Type 1 (IDDM) 2.Type 2 (NIDDM) 3.MODY (Maturity-onset diabetes) 4.Gestational diabetes

16. Type 1 diabetes Type 1 diabetes is defined by an absolute requirement of exogenous insulin results from the autoimmune destruction of insulin-secreting pancreatic B c ells. Type 1 diabetes prone to ketoacidosis and exogenous insulin is required to prevent ketosis. Type 2 diabetes Type 2 diabetes is characterized by a relative insulin deficiency due to insulin secretory defect with insulin resistance. Ketoacidosis is absent. Common risk factors: obesity, genetics.

17. Etiology/causes of Diabetes Type 2 Diabetes Obesity Insulin resistance Genetic factors (family history of diabetes) Type 1 Diabetes The common causes of type 1 diabetes (90% cases) is autoimmune destruction of B cells. Environmental factors (virus and dietary component Genetic factors (HLA antigen) Autoimmune destruction of B cell HLA, Human leukocyte antigen

18. Important feature of type 1 and type 2 diabetes Clinical & other features Type 1Type 2 Age of onsetUsually <30Usually >40 WeightNon-obeseUsually obese KetosisCommonRare Plasma glucose levelHigh Mild to moderate Islet cell mass Severely reduced Moderately reduced AutoantibodiesPresentAbsent Family history of diabetes UncommonCommon

19. Mechanism of insulin secretion Insulin

20. AA, arachadonic acid; AC, adenylyl cyclase; Ach, acetylcholine; CaM PK, calmodulin-dependent kinase; CCK, cholecystokinin; DAG, diacylglycerol; GK, glucokinase; GIP, gastric inhibitory polypeptide; G p, G protein; IP 3, inositol 1,4,5-triphosphate; PKA, protein kinase A; PKC, protein kinase C; PLA 2, phospholipase A 2 ; PLC, phospholipase C.

21. M/A of Sulphonylurea

22. GLP, GIP 5-AMP PDE Insulin release

23. Ach, CCK Insulin secretion Ca 2+ RX871024 + Imidazoline compd (RX871024)  DAG level & activates PKC Troglitazone

24. Diabetes therapy The goal of diabetes management is to achieve as near normoglycemia as in practicable. 1.Diet 2.Insulin 3.Oral hypoglycemic agents (sulphonylyurea or biguanide)

25. 1. Sulphonylurea ( insulin secretagogue) First generation  tolbutamide  tolazamide  acetohexamide Second generation  glibenclamide  glipizide  gliclazide 2. Biguanide  metformin  phenformin  buformin 3. a-glucosidase inhibitors  acarbose ibitor 4. Thiazolidinediones (insulin sensitizers)  troglitazone  pioglitazone  rosiglitazone 5. Meglitinides ( insulin secretagogue)  repaglinide Drugs in pipeline Ö glucagon-like-peptide 1 (GLP- 1) and analogues Ögastric inhibitory polypeptide (GIP) and analogues Ö Amylin Antidiabetic drugs

26. Principal modes and sites of action of antidiabetic drugs Liver  glucose output Metformin Thiazolinediones Pancreas  Insulin secretion Sulphonylureas Meglitinides, GLP-1 Gut Delayed glucose absorption a-glucosidase inhibitors (eg. Acarbose) Metformin, GLP-1 Muscle & Adipose tissue  Peripheral glucose uptake Metformin  Insulin sensitivity Thiazolidinediones, Amylin

27. Antidiabetic drugs: main modes of action DrugMain actions Insulin  HGO peripheral glucose utilization Sulphonylureas  Insulin release Metformin *  Insulin resistance Acarbose §  Rate of carbohydrate digestion Troglitazone   Actions of insulin Repaglinide   Postprandial insulin release * Biguanide; §  glucosidase inhibitor,  thiazolidinedione;  non-sulfonylurea insulin release. HGO, hepatic glucose output.

28. M/A of Sulphonylurea Sulpholylurea

29. GLP, GIP 5-AMP PDE Insulin release IBMX Piperazine GLP-1 receptor agonist : Extendin (newer drug) Extendin

30. Ach, CCK Insulin secretion Ca 2+ RX871024 + Imidazoline compd (RX871024)  DAG level & activates PKC Troglitazone